Search results for: Combination Therapies
Filter search results
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
30 November 2022
…components of a combination therapy gives rise to several challenges for companies, payers and HTA bodies particularly when two or more of the products in combination are owned by different…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…access to combination therapies, including the prevailing pricing models used in Europe. Key takeaways Combination therapies (CTs) can provide effective treatment options and improve patient outcomes, but the lack of…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…address the challenges of combination therapies in the near future. Progress depends upon finding ways of aligning individual drug prices with the value attributable to them in that combination –…
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
…25(11), pp.1821–1827. 10.1016/j.jval.2022.06.009. Towse A., Lothgren M., Bruce A, & Steuten L. (2022) Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies. OHE Consulting Report. Available from https://www.ohe.org/publications/proposal-general-outcome-based-value-attribution-framework-combination-therapies….
Unlocking the Value of Combination Therapies
9 July 2024
Share this: Download publication George Bray Lotte Steuten Gayathri Kumar Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone….
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…adherence in all cases and the prolonged treatment effect of LA therapies may extend or lead to different side effects compared to short-acting therapies. Quality of life (QoL): LA therapies…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…discounting to gene therapies could delay or prevent patients from accessing potentially transformative therapies. The discounting challenge is not unique to gene therapies. Other health technologies like cell therapies, vaccines,…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
…in combination treatments. It sets out two key concepts required for an understanding of the relative performance of a combination regimen as compared to a monotherapy, considering (i) additive scale…
The Price of Success: Can innovative payment models support access to combination therapies in Europe?
5 December 2024, 3:00pm
This panel considered the arguments for and against a system of differential pricing for combination therapies in Europe. They debated whether approaches to pricing in Europe are ready for new…